Fan Xionglin, Gao Qian, Fu Ruiling
Laboratory of Biosafety, Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, PR China.
Microbiol Res. 2009;164(4):374-82. doi: 10.1016/j.micres.2007.04.006. Epub 2007 Aug 30.
BALB/c mice were vaccinated three times (2-week intervals) with plasmid DNA separately encoding antigen Ag85B, ESAT-6 or Ag85A from Mycobacterium tuberculosis. The protective efficacy of these DNA vaccines against intravenous M. tuberculosis H37Rv challenge infection was measured by counting bacterial loads in spleen and lung and recording changes in lung pathology. The splenocyte proliferative response to the corresponding antigens and antigen-specific interferon (IFN)-gamma secreted by splenocytes of the vaccinated mice were also detected. We found a clear hierarchy of protective efficacies among the three DNA vaccines tested in this study. Plasmid DNA encoding Ag85A provided the strongest protection and showed the least change in lung pathology, followed by plasmid DNAs encoding Ag85B and ESAT-6. However, DNA-85B reduced comparative bacterial load in lung tissue, as did DNA-85A. Compared to the control group, protective efficacies conferred by different DNA vaccines were consistent with the lymphoproliferative responses to the corresponding antigens as well as the secretions of antigen-specific IFN-gamma. Our study demonstrates that both Ag85A and Ag85B are the most promising of the candidate antigens tested for future TB vaccine development.
将BALB/c小鼠分别用编码结核分枝杆菌抗原Ag85B、ESAT-6或Ag85A的质粒DNA进行三次免疫接种(间隔2周)。通过计数脾脏和肺部的细菌载量以及记录肺部病理学变化,来测定这些DNA疫苗对静脉注射结核分枝杆菌H37Rv攻击感染的保护效力。还检测了接种疫苗小鼠的脾细胞对相应抗原的增殖反应以及脾细胞分泌的抗原特异性干扰素(IFN)-γ。我们发现在本研究中测试的三种DNA疫苗之间存在明显的保护效力层次结构。编码Ag85A的质粒DNA提供了最强的保护,并且肺部病理学变化最小,其次是编码Ag85B和ESAT-6的质粒DNA。然而,DNA-85B与DNA-85A一样,降低了肺组织中的相对细菌载量。与对照组相比,不同DNA疫苗赋予的保护效力与对相应抗原的淋巴细胞增殖反应以及抗原特异性IFN-γ的分泌一致。我们的研究表明,Ag85A和Ag85B都是未来结核病疫苗开发测试的最有前景的候选抗原。